Cancer Immune Evasion: Targeting the Glycocalyx and Siglec Receptors

Understanding Cancer Immune Evasion

• 💡 Cancer cells have evolved mechanisms to evade the immune system, which is otherwise capable of eliminating transformed cells.
• 🎯 The cancer glycocalyx, a complex carbohydrate coating on cells, plays a significant role in this immune evasion.
• 🚀 Immunotherapy offers a revolutionary approach to treat incurable cancers by preventing this immune escape.

The Role of Immune Checkpoints

• 🔑 Successful tumors often develop molecules that send inhibitory signals to immune cells, particularly T-cells.
• 🧠 Therapies like those used by Jimmy Carter block these inhibitory signals (e.g., PD1, CTLA4) between T-cells and cancer cells.
• ✅ This intervention rebalances the equation, allowing activating signals to dominate and T-cells to effectively kill cancer cells.

Glycosylation and Siglec Receptors

• 🔬 Altered glycosylation is a well-documented characteristic of cancer cells, often correlating with poor clinical outcomes.
• 🧬 The Siglec family of receptors (sialic acid binding immunoglobulin superfamily lectins) are widely expressed on immune cells.
• ⚠️ These Siglec receptors possess ITIM domains that can recruit phosphatases, delivering inhibitory signals to immune cells.

A New Hypothesis for Immune Escape

• 💡 The hypothesis proposes that hyper-sialylation within the cancer glycocalyx serves as a survival adaptation for tumor cells.
• 🛡️ This hyper-sialylation protects cancer cells from immune surveillance by mediating Siglec-ligand interactions.
• 📌 This suggests that Siglecs may function as novel checkpoint receptors in the context of tumor immune evasion.

Therapeutic Strategies

• 🛠️ Research focuses on intervening in this process by targeting the cancer glycocalyx with therapeutic modalities.
• 🧪 A promising approach involves designing antibody-enzyme conjugates, which are biotherapeutic molecules.
• 🔥 These conjugates selectively remove sialic acids from tumor cells, thereby rendering them susceptible to immune cell killing.